Equity Research Analysis: Beta Bionics, Inc. (BBNX)
|Blank Capital Research Unit|Spot: $13.41
Price$13.41
Composite Score34.9/100
RatingAVOID (1★)
Rank#4118 OF 7,333
Market Cap$867M
IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4118
Positioning
Market Dominance
Manufacturing
Medical Equipment
$867M
Sean Saint
We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Our principal executive offices are located at 11 Hughes, Irvine, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BBNX Beta Bionics, Inc. | 35 | 43 | 41 | 23 | - | - | -19.3% | -17.2% | 55.5% | -62.5% | -52.1% | 63.1% | 0.0% | 12.0x | $867M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Beta Bionics, Inc. (BBNX) receives a "Avoid" rating with a composite score of 34.9/100. It ranks #4118 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for BBNX.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 43 | 31 | +12ALPHA |
| MOMENTUM | 23 | 11 | +12ALPHA |
| VALUATION | 41 | 30 | +11ALPHA |
| INVESTMENT | 29 | 35 | -6DRAG |
| STABILITY | 36 | 24 | +12ALPHA |
| SHORT INT | 41 | 37 | +4NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -19.3% (sector -1.9%)
GM 55% vs sector 44%, OM -63% vs sector 3%
Capital turnover N/A, R&D intensity 36.2%
Rev growth 63%, 2yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Beta Bionics, Inc. (BBNX) as Avoid with a composite score of 34.9/100 at a current price of $13.41. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Beta Bionics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.9/100 places it at rank #4118 in our full universe.
Narrow
High
Poor
Fair Value
Gross margins of 55% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Beta Bionics, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Beta Bionics, Inc. with an Avoid rating, assigning a composite score of 34.9/100 and 1 out of 5 stars. Ranked #4118 of 7,333 stocks, BBNX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
BBNX's quality score of 43/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -19.3% (sector avg: -1.9%), gross margins of 55.5% (sector avg: 44.1%), net margins of -52.1% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 41/100, BBNX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 2.06x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Beta Bionics, Inc.'s investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 63.1% vs. a sector average of 6.7% and a return on assets of -17.2% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Beta Bionics, Inc. is experiencing notably weak momentum with a score of just 23/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 63.1% year-over-year, while a beta of 1.71 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
BBNX's stability score of 36/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.71 and a debt-to-equity ratio of 12.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 41/100 for BBNX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 1.71), elevated leverage (D/E: 12.00x), small-cap liquidity risk. With a $867M market cap (small-cap), Beta Bionics, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Beta Bionics, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4118 of 7,333 overall (44th percentile). Key comparisons include ROE of -19.3% trailing the -1.9% sector median and operating margins of -62.5% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While BBNX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (23) would have the largest impact on the composite score.
ROE 915% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 26% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 2592% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time). A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabio
Beta Bionics (BBNX) just closed out FY 2025 with Q4 revenue of US$32.1 million and a net loss of US$13.5 million, which translated to EPS of US$0.30 loss, while trailing 12 month revenue reached US$100.3 million alongside a net loss of US$73.2 million and EPS of US$1.81 loss. Over recent quarters the company has seen revenue move from US$17.6 million and EPS of US$0.93 loss in Q1 2025 to US$27.3 million and EPS of US$0.33 loss in Q3 2025, before landing at the latest Q4 run rate. For...
Operator: Good day, and thank you for standing by. Welcome to the Beta Bionics Inc. Q4 and Full Year 2025 Earnings Conference Call and Webcast.
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $25 to $22.
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $28 to $14.